Skip to main content
F

Fujian Haixi Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 2637 HKEX Manufacturing
Open in API
Filings indexed 37 across all filing types
Latest filing 2026-02-05 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2637

About Fujian Haixi Pharmaceuticals Co., Ltd.

http://www.hxpharma.com

Fujian Haixi Pharmaceuticals Co., Ltd. is a commercial-stage pharmaceutical company integrating R&D, production, and sales capabilities. The company operates primarily under the Market Authorization Holder (MAH) framework, enabling an asset-light business model. Haixi Pharma pursues a dual-line development strategy, balancing generic drugs and innovative drugs. Its generic portfolio emphasizes first-to-file, difficult-to-imitate, and high-quality products, leveraging national pharmaceutical policies. As of late 2025, the company had 15 approved generic drugs commercialized, primarily targeting digestive system diseases and cardiovascular system diseases, with a broader therapeutic scope including oncology, ophthalmology, endocrine, nervous systems, and inflammation. The innovative drug pipeline focuses on developing small-molecule drugs with significant unmet medical needs and global market potential, exemplified by its lead program, C019199.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Stock Exchange. This is a standard regulatory filing required by the HKEX Listing Rules to report monthly movements in securities, share capital, and public float. It does not fit into specific categories like 'Share Issue' (SHA) or 'Transaction in Own Shares' (POS) because it is a recurring regulatory reporting form that covers all movements (or lack thereof) for the month. Therefore, it is classified as a Regulatory Filing (RNS).
2026-02-05 English
DISCLOSEABLE TRANSACTION SUBSCRIPTIONS OF FINANCIAL PRODUCTS
Capital/Financing Update Classification · 1% confidence The document is an official announcement from Fujian Haixi Pharmaceuticals Co., Ltd. regarding a 'Discloseable Transaction' involving the subscription of financial products. It details the terms, parties involved, and the rationale for these investments. Under the Hong Kong Stock Exchange listing rules, such transactions are classified as discloseable transactions, which are regulatory announcements. Since it does not fit into specific categories like M&A (TAR) or Share Issues (SHA), and is a formal regulatory disclosure of a corporate action, it is best classified as a Regulatory Filing (RNS).
2026-02-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies to report monthly movements in securities, including share capital, issued shares, and treasury shares. Since it details changes in share capital and securities, it falls under the category of share issues and capital changes.
2026-01-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. While it relates to share capital, it is a recurring regulatory filing rather than a specific 'Share Issue/Capital Change' (SHA) announcement for a single event, and it is not a report publication announcement. Given the specific nature of the HKEX FF301 form as a mandatory periodic regulatory disclosure, it fits best under the 'Regulatory Filings' category.
2025-12-02 English
CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVES AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
Board/Management Information Classification · 1% confidence The document is an official announcement from Fujian Haixi Pharmaceuticals Co., Ltd. regarding the resignation and appointment of a Joint Company Secretary, Authorized Representatives, and a Process Agent. It also details a waiver granted by the Stock Exchange regarding compliance with Listing Rules. This content falls squarely under the category of changes to senior management or board-related administrative roles, which is defined as 'Board/Management Information' (MANG).
2025-11-21 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings Classification · 1% confidence The document is a mandatory monthly return filed with the Hong Kong Stock Exchange under Chapter 19B of the Listing Rules, detailing movements in authorised share capital, issued shares, and treasury shares. It is neither an AGM material nor an earnings release or management discussion; rather it is a routine regulatory submission that does not fit any more specific category like share issue announcement or director dealing. Therefore it falls under the general Regulatory Filings category (RNS).
2025-11-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.